Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in ...

-New clinical datafrom second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -

Related Keywords

Richa Kumari ,Kiki Patel ,James Levine ,Fairooz Kabbinavar ,Cardiff Oncology Inc ,Gilmartin Group ,Exchange Commission ,Nasdaq ,Taft Communications ,Chief Medical Officer ,Cardiff Oncology ,Objective Response Rates ,Emergent Adverse Events ,Private Securities Litigation Reform Act ,Oncology Contact ,